This author has yet to write their bio.Meanwhile lets just say that we are proud Haley Chartres contributed a whooping 154 entries.
Botanix Executive Director, Matt Callahan, recently participated in the ShareCafe Small Cap ‘Hidden Gems’ Webinar. His presentation provided an overview of our clinical pipeline, including the significant potential for new dermatology products and opportunities for adding new assets to our pipeline. Matt also shared an update on upcoming clinical and operational milestones for 2022.
Botanix (ASX:BOT) is pleased to share a research report from leading stockbroking firm, Euroz Hartleys, following the release of the Company’s December quarterly report. 2022 is described as “a big year ahead”. Click here to view the report.
Botanix (ASX:BOT) has today published its Quarterly Activities Report and 4C Quarterly Cash Flow Report, for the period ended 31 December 2021. Key highlights from this period include: Botanix’s canine atopic dermatitis program, BTX 1204A, is progressing well. Following the launch in September last year, recruitment has been strong, and the study is on track […]
A recent analysis published in The Lancet has highlighted the need for urgent action to address antibiotic-resistant bacterial infections. New data has revealed that more than 1.2 million people – and potentially millions more – died in 2019 as a direct result of antibiotic-resistant bacterial infections. According to the paper’s co-author Prof Chris Murray: “These […]
Botanix (ASX $BOT) Executive Director, Matt Callahan, spoke with BBC journalist, Vivienne Parry, at the 2022 Edison Open House: Global Healthcare virtual event this week. He detailed how the Company is harnessing valuable commercial opportunities in its dermatology and antimicrobial programs: “This is a great time to be in dermatology. There’s a real dearth of […]
Botanix is one of only 34 companies selected to participate in the 2022 Edison Open House: Global Healthcare virtual event to be hosted by the Edison Group next week. Join Botanix’s Executive Director, Matt Callahan, and science journalist, Vivienne Parry, at 7pm AEST on Tuesday 25th January 2022, as they discuss the upcoming developments for […]
At Botanix, we genuinely believe in the therapeutic potential of CBD to treat serious medical conditions … and clearly we’re not alone. Last month, pharmaceutical company Pfizer announced its entry into the cannabinoid space after sharing news of its planned acquisition of clinical-stage company Arena Pharmaceuticals for a total equity value of around US$6.7 billion. […]
While the world continues to battle COVID-19, experts are concerned that older, sick and vulnerable patients may be at increased risk of AMR. According to an article in The Lancet, 1 in 7 patients hospitalised with COVID-19 have “acquired a dangerous secondary bacterial infection, and 50% of patients who have died had such infections.” At […]
Botanix has today released an updated corporate presentation to the ASX, to support a non-deal investor roadshow underway this week. The latest developments in our antimicrobial resistance (AMR) and dermatology R&D programs, include: Progress with our BTX1801 antimicrobial program and plans for Phase 2 clinical studies in early 2022 Advancement of our BTX1702 clinical trial […]
According to WHO Director-General Tedros Adhanom Ghebreyesus, antimicrobial resistance is “one of the greatest health threats humanity faces today”. The Center for Disease Control and Prevention (CDC) estimates that each year in the U.S., at least 2.8 million people get an antibiotic-resistant infection, and more than 35,000 people die. The reality is, #AMR can affect […]
